Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05222607 · ClinicalTrials.gov registry record
Longitudinal Evaluation and Real-world Evidence of NT201
A clinical trial, sponsored by Merz North America.
- Terminated
- Registry status
- 11
- Enrollment target
NCT05222607 is a clinical trial that was terminated before completion, run by Merz North America. The registered enrollment target is 11 participants.
The verdict
NCT05222607 was terminated before completion, sponsored by Merz North America.
- TERMINATED
- Registry status
- 11 participants
- Enrollment target
Study Summary
This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.
Interventions
- DRUG IncobotulinumtoxinA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-02-10 |
| Est. Completion | 2023-05-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05222607
The ClinicalTrials.gov registry entry for NCT05222607 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merz North America, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IncobotulinumtoxinA is the first listed.
NCT05222607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05222607 about?
NCT05222607 is a clinical study titled "Longitudinal Evaluation and Real-world Evidence of NT201". This study is to collect long-term real-world evidence data from clinics in several countries in order to obtain an improved understanding of the safety and effectiveness of incobotulinumtoxinA in botulinum neurotoxin type A (BoNT-A) treatment naïve participants.
What is the current status of trial NCT05222607?
This trial is currently terminated. The enrollment target is 11 participants. The study started on 2023-02-10. Estimated completion is 2023-05-18.
What interventions are being tested in trial NCT05222607?
The interventions under investigation include: IncobotulinumtoxinA (DRUG).
Who is sponsoring clinical trial NCT05222607?
This trial is sponsored by Merz North America, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.